Arctic Bioscience AS (OSL:ABS)

Market Cap	91.38M -22.2%
Revenue (ttm)	45.90M +44.0%
Net Income	-43.36M
EPS	-1.66
Shares Out	26.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,825
Average Volume	13,883
Open	3.160
Previous Close	3.450
Day's Range	3.000 - 3.390
52-Week Range	2.500 - 5.000
Beta	1.09
RSI	51.58
Earnings Date	May 7, 2026

About Arctic Bioscience AS

Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Oslo Børs
• Ticker Symbol: ABS

Financial Performance

In 2024, Arctic Bioscience AS's revenue was 44.40 million, an increase of 31.55% compared to the previous year's 33.76 million. Losses were -47.93 million, 5.31% more than in 2023.